KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Cardlytics (CDLX) over the last 9 years, with Q3 2025 value amounting to $4.4 million.

  • Cardlytics' Capital Expenditures fell 631.58% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 140.69%. This contributed to the annual value of $17.7 million for FY2024, which is 5126.65% up from last year.
  • According to the latest figures from Q3 2025, Cardlytics' Capital Expenditures is $4.4 million, which was down 631.58% from $4.3 million recorded in Q2 2025.
  • In the past 5 years, Cardlytics' Capital Expenditures ranged from a high of $4.8 million in Q3 2024 and a low of $1.9 million during Q1 2021
  • In the last 5 years, Cardlytics' Capital Expenditures had a median value of $3.1 million in 2023 and averaged $3.4 million.
  • In the last 5 years, Cardlytics' Capital Expenditures skyrocketed by 10856.83% in 2021 and then tumbled by 2663.84% in 2023.
  • Over the past 5 years, Cardlytics' Capital Expenditures (Quarter) stood at $2.4 million in 2021, then grew by 24.48% to $3.0 million in 2022, then rose by 15.25% to $3.4 million in 2023, then increased by 26.0% to $4.3 million in 2024, then grew by 3.18% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $4.3 million for Q2 2025, and $4.0 million during Q1 2025.